Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend offered something of a respite, such as it is. In any event, the time has come to resume whatever resembles your new routine. Zoom and Skype meetings may be high on the list, yes? So it’s time to fire up the coffee kettle — our choice today is caramel vanilla cream — and get cracking. As always, we have assembled a few tidbits to help you on your journey. We hope all goes well today and, of course, do stay safe …

Novartis (NVS) reached agreement with the Food and Drug Administration to run a Phase 3 clinical trial to evaluate hydroxychloroquine for treating about 440 hospitalized Covid-19 patients, STAT says. The drug will be supplied by Sandoz, its generics unit, and enrollment will begin at more than a dozen sites in the U.S. within the next few weeks. Novartis will make any intellectual property within its control relating to the use of hydroxychloroquine for treating or preventing Covid-19 available through non-exclusive, voluntary licenses or waivers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.